Astellas Pharma has terminated its discussions with the Chemo-Sero-Therapeutic Research Institute (Kaketsuken), a Kumamoto,Japan-based organization that researches, develops, manufactures, and supplies vaccines and blood plasma products, with respect to the potential transfer of business.

The decision will not affect the existing agreement with Kaketsuken and associated businesses. Astellas will continue making efforts on providing appropriate information and providing stable supply as a distributor of products of Kaketsuken.

Source: Astellas Pharma